Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital
• Treatments: Bevacizumab

Criteria

Inclusion criteria:

• CSC of >4 months duration

Exclusion Criteria:

• History of macular or chorioretinal inflammation

• Lens / corneal opacities